xpeer logo
© Xpeer 2026 All rights reserved
Privacy Policy - Terms of Use - Help

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account
Course Preview

Advances in next-generation CAR T-cell therapy platforms for large B-cell lymphoma (LBCL)

Accredited (Credits: 1)
Free
1h 12min
Audio: English +1
Subtitles: English +1

Synopsis

In this webinar, experts on CAR T-cell therapy will present critical 2025 breakthroughs for high-risk and relapsed/refractory LBCL. The panel explores innovations in rapid manufacturing, dual-targeting, and allogeneic platforms designed to optimise T-cell fitness and delivery. Key discussions address strategic therapy sequencing and practical solutions to improve global patient accessibility for curative-intent care. This activity is for healthcare professionals outside of the USA and UK. This independent medical education is supported by Novartis and is provided by Springer Health+ IME.

This activity is supported by an independent support grant from Springer

Objectives

After completing this activity, participants should be better prepared to:

  • Recognise challenges with currently approved CAR T-cell therapy platforms for patients with relapsed/refractory large B-cell lymphoma
  • Describe the differences between traditional and next-generation CAR T-cell platforms
  • Recall clinical trial data for investigational CAR T-cell therapies

Accreditation

This course is accredited with 1 ECMEC credit valid in 26 countries. To claim your credits take the evaluation (satisfaction survey and evaluation questionnaire). You have 3 attempts for the evaluation. You need to pass the evaluation with a sufficient score to validate the course. Your diploma is issued instantaneously and sent to your email.

See more information on the accreditation at: Accreditation

Duration

1h 12min

Target audience

Hematology, Medical oncology

Authors

Dr. Marco Davila

Marco Davila, MD, PhD, is a physician-scientist and leader in cellular immunotherapy at Roswell Park Comprehensive Cancer Center, where he serves as Senior Vice President and Associate Director for Translational Research. His research focuses on developing next-generation gene-engineered cell therapies, including CAR T-cell therapies, for hematologic malignancies and other cancers.

Conflicts of interests statement:

Receipt of honoraria or consultation fees: CRISPR, Kite, BMS, Adicet, A2 Biotherapeutics

Testimonials

“I've taken several courses on Xpeer and they've been very useful. The format is very dynamic, allowing you to watch the videos in your free time since they're no longer than 15 minutes. The topics are very current.”

Francisco P. onTrustpilot

Spain

“Excellent platform to stay up to date and keep learning throughout your professional career. I recommend it to all my colleagues.”

Omar I. onTrustpilot

Spain

“Xpeer is a magnificent platform for healthcare professionals, where you can gain knowledge from a scientific and highly up-to-date perspective across various medical specialties.”

Wil A. onTrustpilot

Netherlands

Read more reviews onTrustpilot

FAQs

What you will learn

Before you begin

  • Pre-course assessment: please complete to help us personalize your learning experience

Fundamentals and current landscape of CAR T-cell therapies

  • Principles of CAR design and manufacturing
  • Approved therapies and patient eligibility
  • Current challenges and areas of improvement

Key aspects of holding and bridging therapies

  • Holding and bridging therapies: an overview
  • Holding therapy considerations
  • Bridging therapy considerations

Investigational next-generation platforms

  • Benchmarks for rapid manufacturing
  • Dual-targeting and bicistronic cell therapies: clinical data
  • Key concepts for emerging platforms
  • ASH 2025 highlights

Expert discussion

  • Integrating CAR T-cell therapy into earlier lines of treatment
  • Sequencing strategies: CAR T cells versus bispecifics
  • Improving global accessibility and safety

Accreditation - Evaluation

  • Evaluation survey
  • Multiple-choice test

Register now for free!

Over 100,000 doctors have already joined Xpeer — register now to find out why, and get instant access to this course and many more.

I already have an account